₹-0.10
(Market cap
₹21 Cr
Recently Viewed
Clear AllMarket cap
₹21 Cr
Revenue (TTM)
₹25 Cr
P/E Ratio
10.5
P/B Ratio
0.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹2 Cr
ROE
2.9 %
ROCE
6.2 %
Industry P/E
52.14
EV/EBITDA
4.1
Debt to Equity
0.2
Book Value
₹49.1
EPS
₹1.4
Face value
10
Shares outstanding
13,900,000
CFO
₹44.50 Cr
EBITDA
₹52.09 Cr
Net Profit
₹8.19 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nidan Laboratories
| -19.8 | -6.0 | -3.5 | -26.4 | -28.1 | -- | -- |
|
BSE Healthcare
| 1.8 | 4.5 | 5.7 | 4.6 | 24.6 | 13.6 | 11.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Nidan Laboratories
| -36.0 | -13.8 | -30.8 | -6.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nidan Laboratories
|
15.0 | 20.8 | 24.5 | 2.0 | -- | 2.9 | 10.5 | 0.3 |
| 1,430.9 | 23,978.0 | 2,662.8 | 533.1 | 22.9 | 24.1 | 45.4 | 9.4 | |
| 655.0 | 26,179.1 | 3,626.9 | 315.0 | 15.0 | 13.3 | 87.1 | 11.3 | |
| 611.5 | 1,981.7 | 766.3 | 80.5 | 15.7 | 8.9 | 24.7 | 2.1 | |
| 472.2 | 9,793.1 | 1,566.5 | 169.5 | 14.8 | 12.7 | 58.2 | 6.5 | |
| 540.2 | 5,412.4 | 755.8 | 67.1 | -- | 13.8 | 80.7 | 5.6 | |
| 269.3 | 855.1 | 1,231.3 | 29.1 | -4.7 | 4 | 32.9 | 1.3 | |
| 280.7 | 1,457.2 | 294.1 | 32.4 | 17.4 | 15.1 | 43.8 | 6.1 | |
| 395.2 | 6,287.0 | 792.3 | 135.5 | 23.5 | 26.4 | 45.7 | 9.4 | |
| 1,029.5 | 9,954.7 | 768.1 | 159.9 | 29.2 | 19.3 | 62.4 | 11.0 |
No Review & Analysis are available.
Hospital activities
Incorporated
2000
Chairman
--
Managing Director
--
Headquarters
Palghar, Maharashtra
Website
Looking for more details about Nidan Laboratories And Healthcare Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Nidan Laboratories And Healthcare Ltd is ₹14.95 (NSE) as of 23-Apr-2026 IST. Nidan Laboratories And Healthcare Ltd has given a return of -28.15% in the last 3 years.
The P/E ratio of Nidan Laboratories And Healthcare Ltd is 10.51 times as on 23-Apr-2026, a 80 discount to its peers’ median range of 52.14 times.
The P/B ratio of Nidan Laboratories And Healthcare Ltd is 0.30 times as on 23-Apr-2026, a 96 discount to its peers’ median range of 7.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
11.64
|
0.34
|
|
2024
|
0.00
|
0.57
|
|
2023
|
13.29
|
0.68
|
|
2022
|
17.33
|
0.70
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Nidan Laboratories And Healthcare Ltd are Rs 24.90 and Rs 12.75 as of 23-Apr-2026.
Nidan Laboratories And Healthcare Ltd has a market capitalisation of ₹ 21 Cr as on 23-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nidan Laboratories And Healthcare Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.